vo nails

By comparison, CBDA has attracted much less attention from the public, the scientific community, and the media, despite being the precursor to CBD formation and showing promise in early pre-clinical research. But now, a trend of raw juicing cannabis and the advertisement of combination CBD and CBDA cannabis oils has thrust CBDA back into the spotlight, leaving many wondering what exactly is the difference between the two similarly named compounds. All of the major cannabinoids present in cannabis and hemp first develop as “the mother of all cannabinoids,” cannabigerolic acid (CBGA). From there, plant enzymes unique to each cannabis strain convert the CBGA into some varying combination of the three major cannabinoid precursor compounds: tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA), cannabidiolic acid (CBDA). Conversion of cannabigerolic acid (CBGA), to cannabidiolic acid (CBDA), to cannabidiol (CBD) Once CBDA has been formed, it’s then converted into CBD by thermal decarboxylation, whereby heat causes the molecule to lose its acidic carboxyl group.

This decarboxylation process can either happen instantly , such as when the cannabis material is lit and smoked or vaporized, or by slow degradation over time if the plant material is left to sit at room temperature. So, despite being abundant in raw cannabis, cannabis users are not actually exposed to much CBDA, as it’s converted from its “raw” form into CBD by most of the common consumption methods. For people who want to be consuming CBDA, this means having to use more uncommon or conventional consumption methods, such as topical creams, tinctures, and joining in on the raw cannabis juice trend. But why would people go to such lengths to get a dose of CBDA in the first place? What does the raw CBD precursor offer that CBD itself does not? Normally, CBDA and the other acidic forms of cannabinoids are not considered to be pharmacologically active . This is because they don’t affect the body’s endocannabinoid system in the same way that their decarboxylated forms do. As a result, most research has focused on the effects of CBD and THC, rather than CBDA and THCA. But new research is beginning to challenge this idea. It all began in 2008, when researchers noticed that the molecular structure of CBDA closely resembled that of other common nonsteroidal anti-inflammatory drugs (NSAIDs).

The team then investigated the potential of CBDA to act as an anti-inflammatory agent and found that CBDA demonstrated the same COX-2 inhibitor behavior that enables NSAIDs to tackle inflammation. CBDA is also thought to be a powerful treatment for nausea and anxiety. A 2013 study from scientists in Guelph, Canada, found that CBDA was a thousand times more powerful than CBD in binding to a specific serotonin receptor linked to anti-nausea and anti-anxiety effects when administered alongside low-doses of the traditional anti-nausea drug for chemotherapy patients, ondansetron (OND). Despite its demonstrated therapeutic potential, CBDA has not normally been considered as a viable clinical treatment. Naturally, it’s quite an unstable compound – as seen by its gradual decarboxylation at room temperature – and so it wasn’t considered a viable option for clinical treatment. But new research from Dr Raphael Mechoulam – the cannabis scientist who first synthesized THC and CBD – may have broken down that barrier. Speaking at the CannMed 2019 conference in California last month, Dr Mechoulam announced that his research team has found a way to transform the unstable CBDA into a more stable compound which retains the therapeutic potential of CBDA. “We have taken the unstable acid molecules of the cannabis plant and synthesized them to provide a stable, consistent basis for researching new therapies across a wide range of medical needs – from central nervous system disorders to inflammation and many more,” Mechoulam said in a statement . Mechoulam and his research team worked to stabilize the CBDA by converting it into a methyl ester derivative, known as cannabidiolic acid methyl ester, or HU-580. By testing the new compound in an animal model for depression, the researchers confirmed that compound still retains its ability to reduce anxiety-like behaviors, while being chemically stable enough to hold up as a clinical drug. Synthesis of cannabidiolic acid metal ester, HU-580 (right) from cannabidiolic acid, CBDA (left) “In addition, we have provided several delivery mechanisms including tablets, topical applications and others to facilitate several approaches,” said Mechoulam. “Our work is a catalyst for the development of potential new therapies from a source long thought to have huge potential.” The discovery was made by an international collaboration of scientists from several universities in Israel, Canada, and the United States, a topical cream manufacturer, a testing lab, and the start-up company EPM. The latter has now opened its intellectual property portfolio to the healthcare industry for licensing partnerships, in the hopes of attracting further investment. The company hopes that the compound will begin Phase 1 FDA clinical trials within the next six to twelve months. Alexander Beadle has been working as a freelance science writer since 2017 and has covered the cannabis industry for Analytical Cannabis since 2018. He has also written for our sister publication, Technology Networks, and the cannabis industry consultant firm Prohibition Partners, among others. Alexander holds an MChem in materials chemistry from the University of St Andrews, where he won a Chemistry Purdie Scholarship and conducted research into zeolite crystal growth mechanisms and the action of single-molecule transistors. You can find similar content on the topic tag shown below. Stay connected with the latest news in cannabis extraction, science and testing. Get the latest news with the FREE weekly Analytical Cannabis newsletter. Mini Glass Round Jar with Latch by ArtMinds™ Product Actions. Mini Glass Round Jar with Latch by ArtMinds™ Mini Glass Round Jar with Latch by ArtMinds™ Details. Clear glass 1.77" diameter 3.23" height 90 ml Round jar with latch. Clear glass 1.77" diameter 3.23" height 90 ml Round jar with latch. Clear glass 1.77" diameter 3.23" height 90 ml Round jar with latch.

Clear glass 1.77" diameter 3.23" height 90 ml Round jar with latch.

Most products may be shipped via standard ground (delivered in 3-7 business days) or Expedited (1 business day). Orders placed by 11:00 AM Central Time using the Expedited option will ship the same day. If your Michaels purchase does not meet your satisfaction, you may return it within six months (180 days) of purchase. To return an item, the item must be new, unused and in its original packaging.

Menu

Get in touch